Trial Profile
A phase 2, multi-center, open-label, randomized study of mapatumumab (TRM-1 [HGS1012], a fully human monoclonal antibody to TRAIL-R1) in combination with bortezomib (Velcade) and bortezomib alone in subjects with relapsed or refractory multiple myeloma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs Mapatumumab (Primary) ; Bortezomib
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 12 Jun 2011 Results were presented at the 16th Congress of the European Hematology Association.
- 17 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Mar 2011 Planned end date changed from 1 Oct 2008 to 1 Oct 2010 as reported by ClinicalTrials.gov.